The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Drug-Induced Interstitial Lung Disease: A Systematic Review
Open accessAbstract
Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents. Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD. Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3–5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome. Conclusions: Overall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“When used in combination therapy, the rates of DIILD were increased compared to single-agent use [54].”
BackgroundTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
The epidemiology of interstitial lung diseases.
Coultas, D. B., Zumwalt, R. E., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 946
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
A clinical review of bleomycin—a new antineoplastic agent
Blum, R. H., Carter, S. K., & Agre, K. (1973) · Cancer · doi:10.1002/1097-0142(197304)31:4<903::aid-cncr2820310422>3.0.co;2-n · Cited by 864
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., d’Amore, F., Enblad, G., Franceschetto, A., Fulham, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510093 · Cited by 818
Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H., & Hodi, F. S. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2453 · Cited by 758
Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases
Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.-J., & Khamashta, M. A. (2007) · Medicine · doi:10.1097/md.0b013e3181441a68 · Cited by 733
Khunger, M., Rakshit, S., Pasupuleti, V., Hernandez, A. V., Mazzone, P., Stevenson, J., Pennell, N. A., & Velcheti, V. (2017) · Chest · doi:10.1016/j.chest.2017.04.177 · Cited by 502
Nishino, M., Ramaiya, N. H., Awad, M. M., Sholl, L. M., Maattala, J. A., Taibi, M., Hatabu, H., Ott, P. A., Armand, P. F., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1320 · Cited by 499
Kudoh, S., Kato, H., Nishiwaki, Y., Fukuoka, M., Nakata, K., Ichinose, Y., Tsuboi, M., Yokota, S., Nakagawa, K., Suga, M., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200710-1501oc · Cited by 477
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00050-2017 · Cited by 412
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
O’Sullivan, J. M., Huddart, R. A., Norman, A. R., Nicholls, J., Dearnaley, D. P., & Horwich, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg020 · Cited by 378
Ando, M., Okamoto, I., Yamamoto, N., Takeda, K., Tamura, K., Seto, T., Ariyoshi, Y., & Fukuoka, M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9866 · Cited by 362
Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases
Pérez-Álvarez, R., Pérez-De-Lis, M., Díaz‐Lagares, C., Pego‐Reigosa, J. M., Retamozo, S., Bové, A., Brito‐Zerón, P., Bosch, X., & Ramos‐Casals, M. (2011) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.11.002 · Cited by 306
Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris
Duchemann, B., Annesi-Maesano, I., Jacobe de Naurois, C., Sanyal, S., Brillet, P.-Y., Brauner, M., Kambouchner, M., Huynh, S., Naccache, J. M., Borie, R., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02419-2016 · Cited by 304
Roubille, C., & Haraoui, B. P. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.09.005 · Cited by 285
Tirumani, S. H., Ramaiya, N. H., Keraliya, A., Bailey, N. D., Ott, P. A., Hodi, F. S., & Nishino, M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0102 · Cited by 254
Conway, R., Low, C., Coughlan, R. J., O'Donnell, M. J., & Carey, J. J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38322 · Cited by 249
Waxman, H. L., Groh, W. C., Marchlinski, F. E., Buxton, A. E., Sadowski, L. M., Horowitz, L. N., Josephson, M. E., & Kastor, J. A. (1982) · The American Journal of Cardiology · doi:10.1016/0002-9149(82)90419-2 · Cited by 249
Adverse reactions to nitrofurantoin
Holmberg, L., Boman, G., Böttiger, L. E., Eriksson, B., Spross, R., & Wessling, A. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90443-x · Cited by 236
Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
White, D. A., Camus, P., Endo, M., Escudier, B., Calvo, E., Akaza, H., Uemura, H., Kpamegan, E., Kay, A., Robson, M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200911-1720oc · Cited by 210
Rituximab-induced lung disease: a systematic literature review
Lioté, H., Lioté, F., Séroussi, B., Mayaud, C., & Cadranel, J. (2010) · European Respiratory Journal · doi:10.1183/09031936.00080209 · Cited by 181
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis
Suissa, S., Hudson, M., & Ernst, P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21806 · Cited by 174
A cohort study of interstitial lung diseases in central Denmark
Hyldgaard, C., Hilberg, O., Muller, A., & Bendstrup, E. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2013.09.002 · Cited by 171
Koike, T., Harigai, M., Ishiguro, N., Inokuma, S., Takei, S., Takeuchi, T., Yamanaka, H., Haruna, S., Ushida, N., Kawana, K., et al. (2014) · Modern Rheumatology · doi:10.3109/14397595.2013.843760 · Cited by 160
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
Durán, I., Siu, L. L., Oza, A. M., Chung, T., Sturgeon, J. F. G., Townsley, C. A., Pond, G. R., Seymour, L., & Niroumand, M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.015 · Cited by 152
Rituximab‐induced interstitial lung disease
Wagner, S. A., Mehta, A. C., & Laber, D. A. (2007) · American Journal of Hematology · doi:10.1002/ajh.20910 · Cited by 144
Circulating KL-6 levels in patients with drug induced pneumonitis
Ohnishi, H. (2003) · Thorax · doi:10.1136/thorax.58.10.872 · Cited by 144
Diagnostic Significance of Increased Bronchoalveolar Lavage Fluid Eosinophils
Allen, J. N., Davis, W. B., & Pacht, E. R. (1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/142.3.642 · Cited by 140
Weiner, S. M., Sellin, L. K., Vonend, O., Schenker, P., Buchner, N. J., Flecken, M., Viebahn, R., & Rump, L. C. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm420 · Cited by 129
Conway, R. P., Low, C., Coughlan, R. J., O'Donnell, M. J., & CAREY, J. J. (2015) · BMJ · doi:10.1136/bmj.h1269 · Cited by 126
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Tanaka, Y., Yamanaka, H., Fujii, K., Yoshinaga, T., et al. (2011) · Modern Rheumatology · doi:10.1007/s10165-010-0406-3 · Cited by 120
Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 120
Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus
Maroto, P., Hudes, G. R., Dutcher, J. P., Logan, T. F., WHITE, C. S., Krygowski, M., Cincotta, M., Shapiro, M., Durán, I., & Berkenblit, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2235 · Cited by 106
Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate
Ohnishi, K., Sakai, F., Kudoh, S., & Ohno, R. (2006) · Leukemia · doi:10.1038/sj.leu.2404207 · Cited by 104
Statins and Interstitial Lung Disease
Fernández, A. B., Karas, R. H., Alsheikh-Ali, A. A. A., & Thompson, P. D. (2008) · CHEST Journal · doi:10.1378/chest.08-0943 · Cited by 98
Association between anti‐TNF‐α therapy and interstitial lung disease
Herrinton, L. J., Harrold, L. R., Liu, L., Raebel, M. A., Taharka, A., Winthrop, K. L., Solomon, D. H., Curtis, J. R., Lewis, J. D., & Saag, K. G. (2013) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3409 · Cited by 92
Gemma, A., Kudoh, S., Ando, M., Ohe, Y., Nakagawa, K., Johkoh, T., Yamazaki, N., Arakawa, H., Inoue, Y., Ebina, M., et al. (2014) · Cancer Science · doi:10.1111/cas.12550 · Cited by 89
Conway, R. P., Low, C., Coughlan, R. J., O'Donnell, M. J., & CAREY, J. J. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150674 · Cited by 88
Kim, P. W., Sorbello, A. F., Wassel, R. T., Pham, T. M., Tonning, J. M., & Nambiar, S. (2012) · Drug Safety · doi:10.2165/11597460-000000000-00000 · Cited by 84
Nakagawa, K., Kudoh, S., Ohe, Y., Johkoh, T., Ando, M., Yamazaki, N., Seki, A., Takemoto, S., & Fukuoka, M. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182598abb · Cited by 79
Qi, W., Sun, Y., Shen, Z., & Yao, Y. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000189 · Cited by 78
Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
Yang, Z., Yuan, J., Di, M., Zheng, D., Chen, J., Ding, H., Wu, X., Huang, Y., Mao, C., & Tang, J.-L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057528 · Cited by 76
Delorme, S., Keller-Reichenbecher, M.-A., ZUNA, I., Schlegel, W., & KAICK, G. V. (1997) · Investigative Radiology · doi:10.1097/00004424-199709000-00009 · Cited by 76
Iacovelli, R., Palazzo, A., Mezi, S., Morano, F., Naso, G., & Cortesi, E. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.705019 · Cited by 73
Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis
Sharma, A., Provenzale, D., McKusick, A., & Kaplan, M. M. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90085-x · Cited by 67
Ishiguro, M., Watanabe, T., Yamaguchi, K., Satoh, T., Ito, H., Seriu, T., Sakata, Y., & Sugihara, K. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys005 · Cited by 53
Nishino, M., Boswell, E. N., Hatabu, H., Ghobrial, I. M., & Ramaiya, N. H. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0033 · Cited by 52
Wang, Y., Hu, G., Zhang, Q., Tang, N., Guo, J., Liu, L., Han, X., Wang, X., & Wang, Z. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s105442 · Cited by 52
Acute Lung Disease in the Immunocompromised Host
Logan, P. M., Primack, S. L., Staples, C. A., Miller, R. R., & Müller, N. L. (1995) · CHEST Journal · doi:10.1378/chest.108.5.1283 · Cited by 51
Osawa, M., Kudoh, S., Sakai, F., Endo, M., Hamaguchi, T., Ogino, Y., Yoneoka, M., Sakaguchi, M., Nishimoto, H., & Gemma, A. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0834-3 · Cited by 49
Rodríguez-Moreno, A., Ridao, N., García-Ledesma, P., Calvo, N., Pérez-Flores, I., Marqués, M., Barrientos, A., & Sánchez-Fructuoso, A. I. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.06.003 · Cited by 48
Sakurada, T., Kakiuchi, S., Tajima, S., Horinouchi, Y., Okada, N., Nishisako, H., Nakamura, T., Teraoka, K., Kawazoe, K., Yanagawa, H., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014566446 · Cited by 48
Tisdale, J. E., Follin, S. L., Ordelova, A., et al. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04072.x · Cited by 47
Bongard, V., Marc, D., Philippe, V., Montastruc, J., & Lapeyre‐Mestre, M. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200607000-00007 · Cited by 45
Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients
Baas, M. C., Struijk, G. H., Moes, D.-J. A. R., van den Berk, I. A. H., Jonkers, R. E., de Fijter, J. W., van der Heide, J. J. H., van Dijk, M., ten Berge, I. J. M., & Bemelman, F. J. (2014) · Transplant International · doi:10.1111/tri.12275 · Cited by 45
Sato, T., Inokuma, S., Sagawa, A., Matsuda, T., Takemura, T., Otsuka, T., Saeki, Y., Takeuchi, T., & Sawada, T. (2009) · Lara D. Veeken · doi:10.1093/rheumatology/kep227 · Cited by 44
Bhatia, S., Hanna, N. H., Ansari, R., Pletcher, W., Einhorn, L. H., Ng, E. W., & Sandler, A. B. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00145-9 · Cited by 40
Johkoh, T., Sakai, F., Kusumoto, M., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.003 · Cited by 37
Lim, K.-H., Yoon, H.-I., Kang, Y. A., Lee, K., Kim, J. H., Bang, S., Lee, J. H., Lee, C., & Lee, J. S. (2010) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2010.25.1.86 · Cited by 36
Pollak, P. T., Sharma, A. D., & Carruthers, S. G. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90971-3 · Cited by 36
Morgan, A. R., Parker, G. J. M., Roberts, C., Buonaccorsi, G. A., Maguire, N. C., Cristinacce, P. L. H., Singh, D., Vestbo, J., Bjermer, L. H., Jögi, J., et al. (2014) · European Journal of Radiology · doi:10.1016/j.ejrad.2014.08.004 · Cited by 34
Self-citationSafety of treatment with high-dose daptomycin in 102 patients with infective endocarditis
Durante‐Mangoni, E., Andini, R., Parrella, A., Mattucci, I., Cavezza, G., Senese, A., Trojaniello, C., Caprioli, R., Diana, M. V., & Utili, R. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.022 · Cited by 34
Boku, N., Sugihara, K., Kitagawa, Y., Hatake, K., Gemma, A., Yamazaki, N., Muro, K., Hamaguchi, T., Yoshino, T., Yana, I., et al. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt196 · Cited by 31
Santos, J. M., Batech, M., Pelter, M. A., & Deamer, R. L. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14072 · Cited by 25
Şahin, İ. H., Geyer, A. I., Kelly, D. W., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.08.003 · Cited by 15
Amar, R. K., Jick, S. S., Rosenberg, D., Maher, T. M., & Meier, C. R. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02187.x · Cited by 14
Cited by
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Interstitial Lung Disease: A Review
Maher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 388
Tsurutani, J., Iwata, H., Krop, I., Jänne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C., Tamura, K., Wise-Draper, T. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1014 · Cited by 354
Powell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100554 · Cited by 270
Metadata
- Authors
- Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J. M., Waterton, J. C., Buch, M., Linton, K., Bruce, I. N., Leonard, C., Bianchi, S., & Chaudhuri, N.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2018-10-15
- Volume
- 7
- Issue
- 10
- Pages
- 356
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2896600370
- Cited by
- 422
- References
- 72
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.